AACR 2023 | Advances in the development of KRAS inhibitors
Pasi Jänne, MD, PhD, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, discusses the latest developments in targeting KRAS-mutant cancers. The approval of sotorasib and adagrasib for patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) has made a significant impact on the treatment landscape. Current KRAS inhibitors may also have potential in gastrointestinal cancers, where G12D inhibitors can target certain subtypes of pancreatic cancer. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
We’ve seen really a dramatic upswing in the therapeutic landscape for KRAS mutant cancers in the last couple of years with two KRAS G12C inhibitors, sotorasib and adagrasib receiving accelerated regulatory approval for KRAS G12C mutant non-small cell lung cancer, which are the first KRAS targeted therapies to be approved for this subset of lung cancer, which is a significant portion of patients with lung cancer...
We’ve seen really a dramatic upswing in the therapeutic landscape for KRAS mutant cancers in the last couple of years with two KRAS G12C inhibitors, sotorasib and adagrasib receiving accelerated regulatory approval for KRAS G12C mutant non-small cell lung cancer, which are the first KRAS targeted therapies to be approved for this subset of lung cancer, which is a significant portion of patients with lung cancer. And these agents have activity in other cancers, colorectal cancers, and other GI cancers with KRAS G12C mutations. And further development is underway as single agents and in combination with these inhibitors. There is also a second wave of new KRAS inhibitors coming different ways of targeting KRAS, G12C as well as inhibitors against the other mutant isoforms of KRAS, which are common in pancreatic cancer, colon cancer, so KRAS G12D, for example. So, I think that there’s a there’s a there’s a lot of movement in this space and I think it will be a very exciting time in drug development and in the therapeutic landscape of patients with KRAS mutant cancers over the next couple of years.
Read more...
